VitroScan presents the classification of cancer patients into responders and non responders to immunotherapy at AACR23

18 April 2023

VitroScan presents the classification of cancer patients into responders and non responders to immunotherapy at AACR23. Our study of 100+ patients displays highly significant immunotherapy response profiles for 35% of the patients tested. Results are generated within 2 weeks.
For more information and application of our ex vivo tumor testing platform reach out to support@vitroscan.nl.

Please click here to download the poster that was presented at AACR23.